Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Complement C1 inhibitor protein - Takeda Inc

Drug Profile

Complement C1 inhibitor protein - Takeda Inc

Alternative Names: C1 Esterase Inhibitor (human); C1 INH-nf; C1-INH; Cetor; Cinryze; SHP-616; SHP616 Liquid; TAK-616

Latest Information Update: 19 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanquin Blood Supply Foundation
  • Developer Sanquin Blood Supply Foundation; Shire; Shire ViroPharma; Takeda; ViroPharma Incorporated
  • Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase III Transplant rejection
  • No development reported Autoimmune haemolytic anaemia; Delayed graft function; Neuromyelitis optica
  • Discontinued Myocardial infarction; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 06 Jun 2019 Shire terminates a phase III trial in Transplant rejection in USA, Canada, Germany, Spain, France, Netherlands because following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility (IV) (NCT02547220)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 21 Jun 2018 Registered for Hereditary angioedema (In children, Prevention) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top